Major Areas of Research
- Severe viral infections in patients with inborn errors of immunity, with particular focus on herpes family and norovirus infections
- Characterization of genetic determinants of severe viral infections
- Therapeutics for severe viral infections in immunocompromised patients including viral specific T-cell therapies
- Clinical trials of human herpesvirus vaccines
Program Description
The clinical program within the Medical Virology Section has 2 main foci: the natural history of viral infections and their intersection with immune defects and early phase therapeutics and vaccines for herpesvirus infections.
Our natural history protocols allow for the clinical, laboratory and genetic assessment of patients with viral infections with particular emphasis on unusual or severe viral infections. Patients are enrolled and then followed longitudinally to investigate clinical course. In addition, the NIH clinical team collaborates with referring physicians to manage underlying immunodeficiency and refractory viral infections.
Our early clinical trials include phase I Epstein-Barr virus (EBV) vaccines as well as upcoming monoclonal antibodies targeting EBV assessing the safety and immunogenicity of novel antiviral therapeutics.
Biography
Dr. Durkee-Shock graduated magna cum laude from the University of Maryland School of Medicine in 2012. She then completed her combined internal medicine and pediatrics residency at the University of Maryland Medical Center / Baltimore Veterans Affairs Hospital prior to joining NIAID for her fellowship in allergy and clinical immunology. In addition, she is currently a master’s degree candidate for the Duke University Clinical Research Training Program, which is a joint program between the NIH and Duke University providing formal training in clinical research, clinical trials, and statistics.
During her fellowship, she joined the Cell Enhancement and Technologies for Immunotherapy Program (CETI) at Children’s National Medical Center (CNMC) under the mentorship of Dr. Catherine Bollard and Dr. Michael Keller with an emphasis on adoptive T cell therapy for viral infections in immunocompromised hosts including SARS-CoV-2 and chronic Norovirus. During this time, she actively collaborated with the Calicivirus and Medical Virology Sections within the Laboratory of Infectious Disease at NIAID, fostering joint translational projects and clinical protocols. She is passionate about her work in the clinic caring for patients with primary immunodeficiencies, as well as seeking new therapies and vaccines against viral diseases.
Research Group
Jeffrey Cohen, M.D., Chief, Medical Virology Section
Kelly Liepshutz PA, MPAS, Clinical Research Directorate
Krista Gangler RN, Protocol Nurse Coordinator
Kayla Morgan, RN BSN, Clinical Trials Research Nurse
Publications
Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, Keller MD, McDermott DH, Rao VK, Dimitrova D, Quiros-Roldan E, Imberti L, Ferrè EMN, Schmitt M, Lafeer C, Pfister J, Shaw D, Draper D, Truong M, Ulrick J, DiMaggio T, Urban A, Holland SM, Lionakis MS, Cohen JI, Ricotta EE, Notarangelo LD, Freeman AF. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Allergy Clin Immunol. 2021 Nov;148(5):1192-1197.
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, Keswani A, Webber KC, Montgomery-Recht K, Walkiewicz M, Notarangelo LD, Burbelo PD, Fuss I, Cohen JI, Bollard CM, Keller MD. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. J Clin Immunol. 2021 Aug;41(6):1146-1153.
Durkee-Shock JR, Kuehn HS, Stoddard J, Niemela JE, Sun G, Keller MD, Rosenzweig S, Milner JD. Recurrent lymphadenitis in a female XIAP/BIRC4 mutation carrier with normal lyonization. J Allergy Clin Immunol Pract. 2021 Feb;9(2):1002-1005.e2.
Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, Durkee-Shock J, Lee PH, Chaudhry K, Webber K, Datar A, Terpilowski M, Reynolds EK, Stevenson EM, Val S, Shancer Z, Zhang N, Ulrey R, Ekanem U, Stanojevic M, Geiger A, Liang H, Hoq F, Abraham AA, Hanley PJ, Cruz CR, Ferrer K, Dropulic L, Gangler K, Burbelo PD, Jones RB, Cohen JI, Bollard CM. SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood. 2020 Dec 17;136(25):2905-2917.
Clinical Trials
Training Program(s)
The clinical program within the Medical Virology Section has 2 main foci: the natural history of viral infections and their intersection with immune defects and early phase therapeutics and vaccines for herpesvirus infections.
Our natural history protocols allow for the clinical, laboratory and genetic assessment of patients with viral infections with particular emphasis on unusual or severe viral infections. Patients are enrolled and then followed longitudinally to investigate clinical course. In addition, the MVS clinical team collaborates with referring physicians to manage underlying immunodeficiency and/or refractory viral infections.
Our current and planned early clinical trials include phase I Epstein-Barr virus (EBV) vaccines and monoclonal antibodies, as well as collaborations with CNH CETI for viral-specific T cell therapies for the treatment and prevention of chronic norovirus infection and COVID-19.
- Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts (ATLANTIC): NCT04691622
- Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection: NCT04645147
- The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise: NCT01011712
Durkee-Shock J, Lazarski CA, Jensen-Wachspress MA, Zhang A, Son A, Kankate VV, Field NE, Webber K, Lang H, Conway SR, Hanley PJ, Bollard CM, Keller MD, Schwartz DM. Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products. Mol Ther Methods Clin Dev. 2022 Jun 9;25:439-447.
Durkee-Shock J, Zhang A, Liang H, Wright H, Magnusson J, Garabedian E, Marsh RA, Sullivan KE, Keller MD; USIDNET Consortium. Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data From the USIDNET Registry. J Allergy Clin Immunol Pract. 2022 May;10(5):1334-1341.e6.
Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, Keller MD, McDermott DH, Rao VK, Dimitrova D, Quiros-Roldan E, Imberti L, Ferrè EMN, Schmitt M, Lafeer C, Pfister J, Shaw D, Draper D, Truong M, Ulrick J, DiMaggio T, Urban A, Holland SM, Lionakis MS, Cohen JI, Ricotta EE, Notarangelo LD, Freeman AF. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Allergy Clin Immunol. 2021 Nov;148(5):1192-1197.
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, Keswani A, Webber KC, Montgomery-Recht K, Walkiewicz M, Notarangelo LD, Burbelo PD, Fuss I, Cohen JI, Bollard CM, Keller MD. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. J Clin Immunol. 2021 Aug;41(6):1146-1153.
Durkee-Shock JR, Kuehn HS, Stoddard J, Niemela JE, Sun G, Keller MD, Rosenzweig S, Milner JD. Recurrent lymphadenitis in a female XIAP/BIRC4 mutation carrier with normal lyonization. J Allergy Clin Immunol Pract. 2021 Feb;9(2):1002-1005.e2.
Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, Durkee-Shock J, Lee PH, Chaudhry K, Webber K, Datar A, Terpilowski M, Reynolds EK, Stevenson EM, Val S, Shancer Z, Zhang N, Ulrey R, Ekanem U, Stanojevic M, Geiger A, Liang H, Hoq F, Abraham AA, Hanley PJ, Cruz CR, Ferrer K, Dropulic L, Gangler K, Burbelo PD, Jones RB, Cohen JI, Bollard CM. SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood. 2020 Dec 17;136(25):2905-2917.
Research Group
Jeffrey Cohen, M.D., Chief, Medical Virology Section
Kelly Liepshutz PA, MPAS, Clinical Research Directorate
Krista Gangler RN, Protocol Nurse Coordinator
Kayla Morgan, RN BSN, Clinical Trials Research Nurse
Training Program
- Severe viral infections in patients with inborn errors of immunity, with particular focus on herpes family and norovirus infections
- Characterization of genetic determinants of severe viral infections
- Therapeutics for severe viral infections in immunocompromised patients including viral specific T-cell therapies
- Clinical trials of human herpesvirus vaccines
Laser Scanning Confocal Systems
The Twinbrook Imaging Facility has two state-of-the-art laser scanning confocal systems to image live cell specimens. The Zeiss LSM 780 is a multiplatform system capable of spectral imaging, intravital imaging, fluorescence lifetime measurements and fluorescence correlation spectroscopy. The LSM 880 is equipped with the super-resolution Airyscan detector and the FAST system, allowing it to achieve close to video rate recording speeds with a single color.
Zeiss LSM 880 Airyscan with FAST
Located in Fishers, room 4S06A.
Spinning Disk Confocal Microscope
Spinning disk confocal microscopy is a fast, wide-field technique that enables users to capture images at 30 frames per second or more. Located in Fishers 5625, room 4S06B, the facility has a Yokogawa CSU-X1 attached to a motorized Nikon Eclipse Ti2.
General SCORE FAQ
Can cell phones be used as synchronized clocks when recording times for time-critical processes or study procedures?
Yes, as cell phones are usually synchronized through A-GPS (Assisted Global Positioning System) via cellular and wireless connections, they can be used for this purpose.
Vaccine Adjuvant Compendium (VAC)
Longitudinal Observations of Vaccine Responses to SARS-CoV-2 and other Emerging Infectious Diseases (COVAC)
Contact Information
Cassie Seamon, RN
Phone: (301) 402-3481
Email: cseamon@cc.nih.gov
SARS-CoV-2 and NIAID-supported Bat Coronavirus Research
An Analysis: Evolutionary Distance of SARS-CoV-2 and Bat Coronaviruses Studied Under the NIH-supported Research Grant to EcoHealth Alliance
The research that NIH approved under the grant to EcoHealth Alliance with a subaward to the Wuhan Institute of Virology in Wuhan, China sought to understand how animal coronaviruses, especially bat coronaviruses, evolve naturally in the environment and have the potential to become transmissible to the human population.
Vaccine Research Center Senior Leadership
PathogenAR Module – Papillomavirus—The HPV Minichromosome
The Papillomavirus: The HPV Minichromosome module is part of the Pathogens in Augmented Reality (PathogenAR) mobile app.
Papillomaviruses replicate in cells of the skin, mouth and anogenital region of the human host. HPV infection can be asymptomatic, cause warts, or disrupt cell growth. On rare occasions, the cell growth becomes uncontrolled, causing cancer. About 5% of cancers worldwide are caused by Human Papillomavirus (HPV).
PathogenAR Module – COVID-19—Nasopharyngeal Swabs
The COVID-19: Nasopharyngeal Swabs module is part of the Pathogens in Augmented Reality (PathogenAR) mobile app.